Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Owlet, Inc.OWLT · Entity 6551 | Director | October 16, 2025 | August 21, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Owlet, Inc.
Report date October 16, 2025 · Filed August 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 134,787 |
Ending reported balance
After 2026-08-12 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2025-10-16 · Grant · Acquired 18,996 · Balance 108,002 F1: This transaction is being reported late due to an administrative oversight. F2: Constitutes restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of the Company's common stock for each RSU upon vesting. The RSUs will fully vest on the earlier of (a) the first anniversary of the date of grant or (b) immediately prior to the next annual meeting of the Company's stockholders after the date of grant, subject to the Reporting Person's continued service to the Issuer through such vesting date. Row 2 · 2026-08-12 · Grant · Acquired 26,785 · Balance 134,787 F1: This transaction is being reported late due to an administrative oversight. F2: Constitutes restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of the Company's common stock for each RSU upon vesting. The RSUs will fully vest on the earlier of (a) the first anniversary of the date of grant or (b) immediately prior to the next annual meeting of the Company's stockholders after the date of grant, subject to the Reporting Person's continued service to the Issuer through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction is being reported late due to an administrative oversight.
F2: Constitutes restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of the Company's common stock for each RSU upon vesting. The RSUs will fully vest on the earlier of (a) the first anniversary of the date of grant or (b) immediately prior to the next annual meeting of the Company's stockholders after the date of grant, subject to the Reporting Person's continued service to the Issuer through such vesting date.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CERNER Corp
Report date November 02, 2018 · Filed November 05, 2018
Section 16 reporting ended · disclosed 2018-11-05. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Indirectby 401(k) Plan | 13,290 |
Reported balance
Holding disclosure · report date 2018-11-02 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 13,290 |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $70.91 · Expires 2025-03-12 | Direct | 73,000 |
Reported balance
Holding disclosure · report date 2018-11-02 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 73,000 |
Livongo Health, Inc.
Report date October 30, 2020 · Filed October 30, 2020
Section 16 reporting ended · disclosed 2020-10-30. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 911,730 |
Reported balance
After 2020-10-30 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2020-10-30 · Disposition to issuer · Disposed 5,000 · Balance 911,730 F1: Represents restricted stock units ("RSUs") voluntarily forfeited to the Issuer. F2: Includes 210 shares acquired under the Livongo Health, Inc. 2019 Employee Stock Purchase Plan on October 28, 2020. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-10-30 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2020-10-30 · Disposition to issuer · Disposed 911,730 · Balance 0 F3: Includes 72,652 RSUs and 491,149 shares of restricted stock. F4: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 5, 2020, by and among the Issuer, Teladoc Health, Inc. ("Teladoc"), and Tempranillo Merger Sub, Inc., a wholly owned subsidiary of Teladoc, each share of the Issuer's common stock was converted into the right to receive 0.5920 of a share of Teladoc common stock and $4.24 in cash, without interest, together with cash in lieu of fractional shares (if any). F5: Pursuant to the Merger Agreement, each outstanding RSU award of the Issuer was converted into a number of RSUs with respect to a number of shares of Teladoc common stock equal to the product of (i) the number of shares of the Issuer's common stock subject to such RSU award immediately prior to the effective time of the merger and (ii) the Equity Award Adjustment Ratio (as defined below) (rounded down to the nearest whole share of Teladoc common stock on an award-by-award basis), subject to the same terms and conditions as were applicable to such Issuer RSU immediately prior to the effective time of the merger (including applicable vesting conditions). F6: The "Equity Award Adjustment Ratio" means the quotient determined by dividing (i) the volume weighted average closing price of the Issuer's common stock on the four trading days ending on October 29, 2020 by (ii) the volume weighted average closing price of Teladoc common stock on the four trading days beginning on October 29, 2020. F7: Pursuant to the Merger Agreement, each outstanding award of restricted stock of the Issuer was converted into an award of a number of shares of restricted Teladoc common stock equal to the product of (i) the number of shares of the Issuer's common stock subject to such restricted stock award immediately prior to the effective time of the merger and (ii) the Equity Award Adjustment Ratio (rounded down to the nearest whole share of Teladoc common stock on an award-by-award basis), subject to the same terms and conditions as were applicable to such Issuer restrict stock award immediately prior to the effective time of the merger (including applicable vesting conditions). |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units ("RSUs") voluntarily forfeited to the Issuer.
F2: Includes 210 shares acquired under the Livongo Health, Inc. 2019 Employee Stock Purchase Plan on October 28, 2020.
F3: Includes 72,652 RSUs and 491,149 shares of restricted stock.
F4: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 5, 2020, by and among the Issuer, Teladoc Health, Inc. ("Teladoc"), and Tempranillo Merger Sub, Inc., a wholly owned subsidiary of Teladoc, each share of the Issuer's common stock was converted into the right to receive 0.5920 of a share of Teladoc common stock and $4.24 in cash, without interest, together with cash in lieu of fractional shares (if any).
F5: Pursuant to the Merger Agreement, each outstanding RSU award of the Issuer was converted into a number of RSUs with respect to a number of shares of Teladoc common stock equal to the product of (i) the number of shares of the Issuer's common stock subject to such RSU award immediately prior to the effective time of the merger and (ii) the Equity Award Adjustment Ratio (as defined below) (rounded down to the nearest whole share of Teladoc common stock on an award-by-award basis), subject to the same terms and conditions as were applicable to such Issuer RSU immediately prior to the effective time of the merger (including applicable vesting conditions).
F6: The "Equity Award Adjustment Ratio" means the quotient determined by dividing (i) the volume weighted average closing price of the Issuer's common stock on the four trading days ending on October 29, 2020 by (ii) the volume weighted average closing price of Teladoc common stock on the four trading days beginning on October 29, 2020.
F7: Pursuant to the Merger Agreement, each outstanding award of restricted stock of the Issuer was converted into an award of a number of shares of restricted Teladoc common stock equal to the product of (i) the number of shares of the Issuer's common stock subject to such restricted stock award immediately prior to the effective time of the merger and (ii) the Equity Award Adjustment Ratio (rounded down to the nearest whole share of Teladoc common stock on an award-by-award basis), subject to the same terms and conditions as were applicable to such Issuer restrict stock award immediately prior to the effective time of the merger (including applicable vesting conditions).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 12, 2026 Filed Aug 21, 2026 20:11 UTC | Owlet, Inc. OWLT · Entity 6551 | GrantCommon Stock | 26,785 | $0.00 | $0.00 |
DisclosureSEC source: 0001213555-26-000004 · wk-form4_1787343096.xml · nonDerivative · entry 2 BURKE ZANE M · CIK 0001213555 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 134,787 F1 · date: This transaction is being reported late due to an administrative oversight. F2 · shares: Constitutes restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of the Company's common stock for each RSU upon vesting. The RSUs will fully vest on the earlier of (a) the first anniversary of the date of grant or (b) immediately prior to the next annual meeting of the Company's stockholders after the date of grant, subject to the Reporting Person's continued service to the Issuer through such vesting date. Read SEC document |
| October 16, 2025 Filed Aug 21, 2026 20:11 UTC | Owlet, Inc. OWLT · Entity 6551 | GrantCommon Stock | 18,996 | $0.00 | $0.00 |
DisclosureSEC source: 0001213555-26-000004 · wk-form4_1787343096.xml · nonDerivative · entry 1 BURKE ZANE M · CIK 0001213555 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 108,002 F1 · date: This transaction is being reported late due to an administrative oversight. F2 · shares: Constitutes restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of the Company's common stock for each RSU upon vesting. The RSUs will fully vest on the earlier of (a) the first anniversary of the date of grant or (b) immediately prior to the next annual meeting of the Company's stockholders after the date of grant, subject to the Reporting Person's continued service to the Issuer through such vesting date. Read SEC document |
| August 16, 2024 Filed Aug 21, 2024 01:47 UTC | Owlet, Inc. OWLT · Entity 6551 | GrantCommon Stock | 34,562 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-037958 · wk-form4_1724204873.xml · nonDerivative · entry 1 BURKE ZANE M · CIK 0001213555 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 89,006 F1 · shares: Constitutes restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of the Company's common stock for each RSU upon vesting. The RSUs are fully vested and settled on the date of grant. Read SEC document |
| July 18, 2023 Filed Jul 21, 2023 01:30 UTC | Owlet, Inc. OWLT · Entity 6551 | GrantCommon Stock | 41,782 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-23-025279 · wk-form4_1689903026.xml · nonDerivative · entry 2 BURKE ZANE M · CIK 0001213555 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,444 F1 · shares: Constitutes restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of the Company's common stock for each RSU upon vesting. The RSUs will vest in full on the earlier of June 23, 2024 or the date of the Company's next annual meeting of stockholders, subject to the Reporting Person's continued service on the Company's board of directors on the vesting date. Read SEC document |
| June 23, 2023 Filed Jul 21, 2023 01:30 UTC | Owlet, Inc. OWLT · Entity 6551 | Exercise / conversionRestricted Stock Units · Derivative | 3,035 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-23-025279 · wk-form4_1689903026.xml · derivative · entry 3 BURKE ZANE M · CIK 0001213555 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,035 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Company's common stock. F3 · derivative.exercise_date: The RSUs vested on June 23, 2023. F3 · derivative.expiration_date: The RSUs vested on June 23, 2023. Read SEC document |
| June 23, 2023 Filed Jul 21, 2023 01:30 UTC | Owlet, Inc. OWLT · Entity 6551 | Exercise / conversionCommon Stock | 3,035 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-23-025279 · wk-form4_1689903026.xml · nonDerivative · entry 1 BURKE ZANE M · CIK 0001213555 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,662 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 25, 2023 Filed Jan 28, 2023 01:22 UTC | Owlet, Inc. OWLT · Entity 6551 | GrantRestricted Stock Units · Derivative | 42,492 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-23-001698 · wf-form4_167486894646757.xml · derivative · entry 1 BURKE ZANE M · CIK 0001213555 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,492 Underlying: Common Stock · 42,492 shares Expires not disclosed F1 · security: With tax withholding rights. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F3 · derivative.exercise_date: The restricted stock units will vest in full on the earlier of June 17, 2023 or the date of the Company's next annual meeting of shareholders, subject to Mr. Burke's continued service on the Company's board of directors on the vesting date. F3 · derivative.expiration_date: The restricted stock units will vest in full on the earlier of June 17, 2023 or the date of the Company's next annual meeting of shareholders, subject to Mr. Burke's continued service on the Company's board of directors on the vesting date. Read SEC document |
| November 15, 2021 Filed Nov 18, 2021 00:47 UTC | Owlet, Inc. OWLT · Entity 6551 | GrantCommon Stock | 32,120 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-020688 · doc1.xml · nonDerivative · entry 1 BURKE ZANE M · CIK 0001213555 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,779 F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 100% of the RSUs shall vest on the one year anniversary of March 12, 2021, subject to the Reporting Person's continued service to the issuer. F2 · balance_after: Includes 32,120 RSUs. Read SEC document |
| July 15, 2021 Filed Jul 20, 2021 00:03 UTC | Owlet, Inc. OWLT · Entity 6551 | GrantCommon Stock | 102,659 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-21-024844 · form4.xml · nonDerivative · entry 1 BURKE ZANE M · CIK 0001213555 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,659 F1 · price: On July 15, 2021, pursuant to that certain Business Combination Agreement, dated as of February 15, 2021, by and among the Issuer, Project Olympus Merger Sub, Inc. ("Merger Sub") and Owlet Baby Care Inc. ("Owlet Baby Care"), Merger Sub merged with and into Owlet Baby Care with Owlet Baby Care surviving as a wholly owned subsidiary of the Issuer (the "Merger"). Upon consummation of the Merger (the "Effective Time"), each issued and outstanding share of common stock of Owlet Baby Care was automatically cancelled and converted into approximately 2.053 (the "Exchange Ratio") shares of common stock of the Issuer. Read SEC document |
| October 30, 2020 Filed Oct 30, 2020 21:17 UTC | Livongo Health, Inc. LVGO · Entity 145566 | Disposition to issuerCommon Stock | 911,730 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001639225-20-000061 · wf-form4_160409262731584.xml · nonDerivative · entry 2 BURKE ZANE M · CIK 0001213555 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F3 · shares: Includes 72,652 RSUs and 491,149 shares of restricted stock. F4 · price: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 5, 2020, by and among the Issuer, Teladoc Health, Inc. ("Teladoc"), and Tempranillo Merger Sub, Inc., a wholly owned subsidiary of Teladoc, each share of the Issuer's common stock was converted into the right to receive 0.5920 of a share of Teladoc common stock and $4.24 in cash, without interest, together with cash in lieu of fractional shares (if any). F5 · price: Pursuant to the Merger Agreement, each outstanding RSU award of the Issuer was converted into a number of RSUs with respect to a number of shares of Teladoc common stock equal to the product of (i) the number of shares of the Issuer's common stock subject to such RSU award immediately prior to the effective time of the merger and (ii) the Equity Award Adjustment Ratio (as defined below) (rounded down to the nearest whole share of Teladoc common stock on an award-by-award basis), subject to the same terms and conditions as were applicable to such Issuer RSU immediately prior to the effective time of the merger (including applicable vesting conditions). F6 · price: The "Equity Award Adjustment Ratio" means the quotient determined by dividing (i) the volume weighted average closing price of the Issuer's common stock on the four trading days ending on October 29, 2020 by (ii) the volume weighted average closing price of Teladoc common stock on the four trading days beginning on October 29, 2020. F7 · price: Pursuant to the Merger Agreement, each outstanding award of restricted stock of the Issuer was converted into an award of a number of shares of restricted Teladoc common stock equal to the product of (i) the number of shares of the Issuer's common stock subject to such restricted stock award immediately prior to the effective time of the merger and (ii) the Equity Award Adjustment Ratio (rounded down to the nearest whole share of Teladoc common stock on an award-by-award basis), subject to the same terms and conditions as were applicable to such Issuer restrict stock award immediately prior to the effective time of the merger (including applicable vesting conditions). Read SEC document |
| October 30, 2020 Filed Oct 30, 2020 21:17 UTC | Livongo Health, Inc. LVGO · Entity 145566 | Disposition to issuerCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001639225-20-000061 · wf-form4_160409262731584.xml · nonDerivative · entry 1 BURKE ZANE M · CIK 0001213555 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 911,730 F1 · shares: Represents restricted stock units ("RSUs") voluntarily forfeited to the Issuer. F2 · balance_after: Includes 210 shares acquired under the Livongo Health, Inc. 2019 Employee Stock Purchase Plan on October 28, 2020. Read SEC document |
| September 08, 2020 Filed Sep 10, 2020 21:37 UTC | Livongo Health, Inc. LVGO · Entity 145566 | Tax withholdingCommon Stock | 48,318 | $123.10 | $5,947,945.80 |
DisclosureSEC source: 0001209191-20-050016 · doc4.xml · nonDerivative · entry 1 BURKE ZANE M · CIK 0001213555 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 916,520 F1 · kind: The reported shares were withheld to satisfy the reporting person's tax liability in connection with the vesting of restricted stock awards. Read SEC document |
| September 03, 2020 Filed Sep 5, 2020 01:04 UTC | Livongo Health, Inc. LVGO · Entity 145566 | SaleCommon Stock | 49,115 | $124.50 | $6,114,817.50 |
DisclosureSEC source: 0001209191-20-049677 · doc4.xml · nonDerivative · entry 1 BURKE ZANE M · CIK 0001213555 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 964,838 F1 · kind: Represents shares sold in the open market to facilitate diversification within the reporting person's overall portfolio. Following the sales reported on this form, the reporting person continues to hold approximately 85% of the vested shares of the Issuer's common stock held immediately prior to such sales. Read SEC document |
| August 26, 2020 Filed Aug 28, 2020 20:09 UTC | Livongo Health, Inc. LVGO · Entity 145566 | SaleCommon Stock | 2,062 | $132.53 | $273,276.86 |
DisclosureSEC source: 0001209191-20-048613 · doc4.xml · nonDerivative · entry 1 BURKE ZANE M · CIK 0001213555 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,013,953 F1 · kind: The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units. F2 · balance_after: Includes 446 shares acquired under the Livongo Health, Inc. 2019 Employee Stock Purchase Plan on May 15, 2020. Read SEC document |
| May 14, 2020 Filed May 18, 2020 22:47 UTC | Livongo Health, Inc. LVGO · Entity 145566 | GrantCommon Stock | 82,828 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-030231 · doc4.xml · nonDerivative · entry 1 BURKE ZANE M · CIK 0001213555 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,015,569 F1 · shares: The reported shares are represented by restricted stock units which vest in 16 equal quarterly installments beginning on August 25, 2020. Read SEC document |
| March 06, 2020 Filed Mar 10, 2020 21:09 UTC | Livongo Health, Inc. LVGO · Entity 145566 | Tax withholdingCommon Stock | 49,560 | $27.84 | $1,379,750.40 |
DisclosureSEC source: 0001209191-20-017759 · doc4.xml · nonDerivative · entry 1 BURKE ZANE M · CIK 0001213555 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 932,741 F1 · kind: The reported shares were withheld to satisfy the reporting person's tax liability in connection with the vesting of restricted stock awards. Read SEC document |
| September 13, 2018 Filed Sep 13, 2018 18:01 UTC | CERNER Corp CERN · Entity 126375 | OtherNon-Qualified Stock Option (right to buy) · Derivative | 97,600 | $62.94 Strike: $62.94 | $6,142,944.00 |
DisclosureSEC source: 0001209191-18-050944 · doc4.xml · derivative · entry 11 BURKE ZANE M · CIK 0001213555 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 97,600 shares Expires 2028-03-02 F4 · derivative.exercise_date: On September 6, 2018, Mr. Burke became fully vested in all outstanding stock options as part of the terms of a Separation Agreement entered into with Cerner Corporation. Read SEC document |
| September 13, 2018 Filed Sep 13, 2018 18:01 UTC | CERNER Corp CERN · Entity 126375 | SaleCommon Stock | 97,600 | $65.14 | $6,357,664.00 |
DisclosureSEC source: 0001209191-18-050944 · doc4.xml · nonDerivative · entry 6 BURKE ZANE M · CIK 0001213555 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Full information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, Cerner Corporation, or a Cerner shareholder. F3 · price: Price reflects a weighted-average price for the transaction. Sale of shares took place at actual prices ranging from $65.00 to $65.40. Read SEC document |
| September 13, 2018 Filed Sep 13, 2018 18:01 UTC | CERNER Corp CERN · Entity 126375 | OtherCommon Stock | 97,600 | $62.94 | $6,142,944.00 |
DisclosureSEC source: 0001209191-18-050944 · doc4.xml · nonDerivative · entry 5 BURKE ZANE M · CIK 0001213555 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,600 Read SEC document |
| September 11, 2018 Filed Sep 13, 2018 18:01 UTC | CERNER Corp CERN · Entity 126375 | OtherNon-Qualified Stock Option (right to buy) · Derivative | 140,000 | $55.74 Strike: $55.74 | $7,803,600.00 |
DisclosureSEC source: 0001209191-18-050944 · doc4.xml · derivative · entry 10 BURKE ZANE M · CIK 0001213555 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 140,000 shares Expires 2027-03-03 F4 · derivative.exercise_date: On September 6, 2018, Mr. Burke became fully vested in all outstanding stock options as part of the terms of a Separation Agreement entered into with Cerner Corporation. Read SEC document |
| September 11, 2018 Filed Sep 13, 2018 18:01 UTC | CERNER Corp CERN · Entity 126375 | OtherNon-Qualified Stock Option (right to buy) · Derivative | 84,000 | $54.01 Strike: $54.01 | $4,536,840.00 |
DisclosureSEC source: 0001209191-18-050944 · doc4.xml · derivative · entry 9 BURKE ZANE M · CIK 0001213555 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 84,000 shares Expires 2026-03-11 F4 · derivative.exercise_date: On September 6, 2018, Mr. Burke became fully vested in all outstanding stock options as part of the terms of a Separation Agreement entered into with Cerner Corporation. Read SEC document |
| September 11, 2018 Filed Sep 13, 2018 18:01 UTC | CERNER Corp CERN · Entity 126375 | OtherNon-Qualified Stock Option (right to buy) · Derivative | 14,600 | $60.37 Strike: $60.37 | $881,402.00 |
DisclosureSEC source: 0001209191-18-050944 · doc4.xml · derivative · entry 8 BURKE ZANE M · CIK 0001213555 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,600 shares Expires 2024-03-07 F4 · derivative.exercise_date: On September 6, 2018, Mr. Burke became fully vested in all outstanding stock options as part of the terms of a Separation Agreement entered into with Cerner Corporation. Read SEC document |
| September 11, 2018 Filed Sep 13, 2018 18:01 UTC | CERNER Corp CERN · Entity 126375 | SaleCommon Stock | 283,539 | $63.68 | $18,055,763.52 |
DisclosureSEC source: 0001209191-18-050944 · doc4.xml · nonDerivative · entry 4 BURKE ZANE M · CIK 0001213555 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Full information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, Cerner Corporation, or a Cerner shareholder. F2 · price: Price reflects a weighted-average price for the transaction. Sale of shares took place at actual prices ranging from $63.11 to $64.10. Read SEC document |
| September 11, 2018 Filed Sep 13, 2018 18:01 UTC | CERNER Corp CERN · Entity 126375 | OtherCommon Stock | 140,000 | $55.74 | $7,803,600.00 |
DisclosureSEC source: 0001209191-18-050944 · doc4.xml · nonDerivative · entry 3 BURKE ZANE M · CIK 0001213555 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 283,539 Read SEC document |
| September 11, 2018 Filed Sep 13, 2018 18:01 UTC | CERNER Corp CERN · Entity 126375 | OtherCommon Stock | 84,000 | $54.01 | $4,536,840.00 |
DisclosureSEC source: 0001209191-18-050944 · doc4.xml · nonDerivative · entry 2 BURKE ZANE M · CIK 0001213555 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,539 Read SEC document |
| September 11, 2018 Filed Sep 13, 2018 18:01 UTC | CERNER Corp CERN · Entity 126375 | OtherCommon Stock | 14,600 | $60.37 | $881,402.00 |
DisclosureSEC source: 0001209191-18-050944 · doc4.xml · nonDerivative · entry 1 BURKE ZANE M · CIK 0001213555 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,539 Read SEC document |
| September 06, 2018 Filed Sep 10, 2018 16:32 UTC | CERNER Corp CERN · Entity 126375 | Exercise / conversionRestricted Stock Units · Derivative | 11,680 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-050267 · doc4.xml · derivative · entry 5 BURKE ZANE M · CIK 0001213555 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,680 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: On September 6, 2018, Mr. Burke became fully vested in all outstanding stock options and restricted stock units as part of the terms of a Separation Agreement entered into with Cerner Corporation. F2 · derivative.expiration_date: On September 6, 2018, Mr. Burke became fully vested in all outstanding stock options and restricted stock units as part of the terms of a Separation Agreement entered into with Cerner Corporation. Read SEC document |
| September 06, 2018 Filed Sep 10, 2018 16:32 UTC | CERNER Corp CERN · Entity 126375 | Exercise / conversionRestricted Stock Units · Derivative | 70,400 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-050267 · doc4.xml · derivative · entry 4 BURKE ZANE M · CIK 0001213555 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 70,400 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: On September 6, 2018, Mr. Burke became fully vested in all outstanding stock options and restricted stock units as part of the terms of a Separation Agreement entered into with Cerner Corporation. F2 · derivative.expiration_date: On September 6, 2018, Mr. Burke became fully vested in all outstanding stock options and restricted stock units as part of the terms of a Separation Agreement entered into with Cerner Corporation. Read SEC document |
| September 06, 2018 Filed Sep 10, 2018 16:32 UTC | CERNER Corp CERN · Entity 126375 | Tax withholdingCommon Stock | 37,141 | $64.89 | $2,410,079.49 |
DisclosureSEC source: 0001209191-18-050267 · doc4.xml · nonDerivative · entry 2 BURKE ZANE M · CIK 0001213555 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,939 F1 · shares: Shares withheld to satisfy the tax withholdings for the vesting of restricted stock units. Read SEC document |
| September 06, 2018 Filed Sep 10, 2018 16:32 UTC | CERNER Corp CERN · Entity 126375 | Exercise / conversionCommon Stock | 82,080 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-050267 · doc4.xml · nonDerivative · entry 1 BURKE ZANE M · CIK 0001213555 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,080 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 28, 2018 Filed Aug 30, 2018 18:02 UTC | CERNER Corp CERN · Entity 126375 | OtherNon-Qualified Stock Option (right to buy) · Derivative | 56,000 | $54.01 Strike: $54.01 | $3,024,560.00 |
DisclosureSEC source: 0001209191-18-048997 · doc4.xml · derivative · entry 8 BURKE ZANE M · CIK 0001213555 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,000 Underlying: Common Stock · 56,000 shares Expires 2026-03-11 Read SEC document |
| August 28, 2018 Filed Aug 30, 2018 18:02 UTC | CERNER Corp CERN · Entity 126375 | OtherNon-Qualified Stock Option (right to buy) · Derivative | 58,400 | $60.37 Strike: $60.37 | $3,525,608.00 |
DisclosureSEC source: 0001209191-18-048997 · doc4.xml · derivative · entry 7 BURKE ZANE M · CIK 0001213555 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,600 Underlying: Common Stock · 58,400 shares Expires 2024-03-07 Read SEC document |
| August 28, 2018 Filed Aug 30, 2018 18:02 UTC | CERNER Corp CERN · Entity 126375 | OtherNon-Qualified Stock Option (right to buy) · Derivative | 16,000 | $44.62 Strike: $44.62 | $713,840.00 |
DisclosureSEC source: 0001209191-18-048997 · doc4.xml · derivative · entry 6 BURKE ZANE M · CIK 0001213555 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,000 shares Expires 2023-03-01 Read SEC document |
| August 28, 2018 Filed Aug 30, 2018 18:02 UTC | CERNER Corp CERN · Entity 126375 | SaleCommon Stock | 151,818 | $65.44 | $9,934,969.92 |
DisclosureSEC source: 0001209191-18-048997 · doc4.xml · nonDerivative · entry 4 BURKE ZANE M · CIK 0001213555 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Price reflects a weighted-average price for the transaction. Sale of shares took place at actual prices ranging from $65.17 to $65.82. F2 · price: Full information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, Cerner Corporation, or a Cerner shareholder. Read SEC document |
| August 28, 2018 Filed Aug 30, 2018 18:02 UTC | CERNER Corp CERN · Entity 126375 | OtherCommon Stock | 56,000 | $54.01 | $3,024,560.00 |
DisclosureSEC source: 0001209191-18-048997 · doc4.xml · nonDerivative · entry 3 BURKE ZANE M · CIK 0001213555 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,818 Read SEC document |
| August 28, 2018 Filed Aug 30, 2018 18:02 UTC | CERNER Corp CERN · Entity 126375 | OtherCommon Stock | 58,400 | $60.37 | $3,525,608.00 |
DisclosureSEC source: 0001209191-18-048997 · doc4.xml · nonDerivative · entry 2 BURKE ZANE M · CIK 0001213555 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,818 Read SEC document |
| August 28, 2018 Filed Aug 30, 2018 18:02 UTC | CERNER Corp CERN · Entity 126375 | OtherCommon Stock | 16,000 | $44.62 | $713,840.00 |
DisclosureSEC source: 0001209191-18-048997 · doc4.xml · nonDerivative · entry 1 BURKE ZANE M · CIK 0001213555 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,418 Read SEC document |
| June 01, 2018 Filed Jun 5, 2018 16:06 UTC | CERNER Corp CERN · Entity 126375 | Tax withholdingCommon Stock | 6,844 | $59.73 | $408,792.12 |
DisclosureSEC source: 0001209191-18-035590 · doc4.xml · nonDerivative · entry 1 BURKE ZANE M · CIK 0001213555 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,418 F1 · shares: Shares of common stock withheld to satisfy the tax withholdings for the vesting of 18,000 shares of restricted common stock. Read SEC document |
| March 05, 2018 Filed Mar 6, 2018 21:35 UTC | CERNER Corp CERN · Entity 126375 | OtherRestricted Stock Units · Derivative | 2,100 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-017574 · doc4.xml · derivative · entry 3 BURKE ZANE M · CIK 0001213555 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,100 shares Expires 2018-03-05 F1 · kind: Vesting of restricted stock units, net of 637 shares withheld to satisfy income tax withholdings. Read SEC document |
| March 05, 2018 Filed Mar 6, 2018 21:35 UTC | CERNER Corp CERN · Entity 126375 | OtherCommon Stock | 1,463 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-017574 · doc4.xml · nonDerivative · entry 1 BURKE ZANE M · CIK 0001213555 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,262 F1 · kind: Vesting of restricted stock units, net of 637 shares withheld to satisfy income tax withholdings. F2 · balance_after: Includes 18,000 shares of restricted common stock. Read SEC document |
| March 02, 2018 Filed Mar 6, 2018 21:35 UTC | CERNER Corp CERN · Entity 126375 | GrantRestricted Stock Units · Derivative | 11,680 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-017574 · doc4.xml · derivative · entry 5 BURKE ZANE M · CIK 0001213555 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,680 Underlying: Common Stock · 11,680 shares Expires 2021-03-02 F5 · shares: Each restricted stock unit represents a contingent right to receive one share of Cerner Corporation common stock. The restricted stock units are eligible for vesting on 03/02/2021. F6 · price: This transaction represents a grant of restricted stock units to the reporting person by the issuer. Therefore, no consideration other than the value of services rendered was paid for the security. Read SEC document |
| March 02, 2018 Filed Mar 6, 2018 21:35 UTC | CERNER Corp CERN · Entity 126375 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 97,600 | $0.00 Strike: $62.94 | $0.00 |
DisclosureSEC source: 0001209191-18-017574 · doc4.xml · derivative · entry 4 BURKE ZANE M · CIK 0001213555 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,600 Underlying: Common Stock · 97,600 shares Expires 2028-03-02 F4 · price: This transaction represents a grant of options to the reporting person by the issuer. Therefore, no consideration other than the value of services rendered was paid for the security. F3 · derivative.exercise_date: Options are exercisable per the following schedule: 40% - 03/02/2020, 20% - 03/02/2021, 20% - 03/02/2022, 20% - 03/02/2023. Read SEC document |
| December 30, 2017 Filed Jan 12, 2018 16:06 UTC | CERNER Corp CERN · Entity 126375 | OtherCommon Stock | 155 | $53.32 | $8,264.60 |
DisclosureSEC source: 0001209191-18-003397 · doc5.xml · nonDerivative · entry 1 BURKE ZANE M · CIK 0001213555 · President 10b5-1 filing: Not disclosed Ownership: Indirect · by 401(k) Plan Disclosed balance after: 13,290 F1 · kind: Represents shares acquired through routine payroll deduction and participation in the issuer's 401(k) plan between 01/01/2017 and 12/30/2017, at prices ranging from $51.23 to $55.51 per share. Balance is based on plan statement as of 12/30/2017. This transaction qualifies as a non-discretionary transaction from a tax-qualified plan. F1 · price: Represents shares acquired through routine payroll deduction and participation in the issuer's 401(k) plan between 01/01/2017 and 12/30/2017, at prices ranging from $51.23 to $55.51 per share. Balance is based on plan statement as of 12/30/2017. This transaction qualifies as a non-discretionary transaction from a tax-qualified plan. F2 · price: Full information regarding the number of shares acquired at each separate price will be provided upon request by the Commission staff, Cerner Corporation, or a Cerner shareholder. Read SEC document |
| December 13, 2017 Filed Dec 13, 2017 16:40 UTC | CERNER Corp CERN · Entity 126375 | SaleCommon Stock | 50,000 | $70.00 | $3,500,000.00 |
DisclosureSEC source: 0001209191-17-065446 · doc4.xml · nonDerivative · entry 1 BURKE ZANE M · CIK 0001213555 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,799 F1 · price: Full information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, Cerner Corporation, or a Cerner shareholder. F2 · price: Price reflects a weighted-average price for the transaction. Sale of shares took place at actual prices ranging from $69.36 to $70.63. F3 · balance_after: Includes 18,000 shares of restricted common stock. Read SEC document |
| September 05, 2017 Filed Sep 6, 2017 16:45 UTC | CERNER Corp CERN · Entity 126375 | OtherNon-Qualified Stock Option (right to buy) · Derivative | 64,000 | $44.62 Strike: $44.62 | $2,855,360.00 |
DisclosureSEC source: 0001209191-17-051657 · doc4.xml · derivative · entry 8 BURKE ZANE M · CIK 0001213555 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 64,000 shares Expires 2023-03-01 Read SEC document |
| September 05, 2017 Filed Sep 6, 2017 16:45 UTC | CERNER Corp CERN · Entity 126375 | OtherNon-Qualified Stock Option (right to buy) · Derivative | 10,000 | $36.96 Strike: $36.96 | $369,600.00 |
DisclosureSEC source: 0001209191-17-051657 · doc4.xml · derivative · entry 7 BURKE ZANE M · CIK 0001213555 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2022-07-31 Read SEC document |
| September 05, 2017 Filed Sep 6, 2017 16:45 UTC | CERNER Corp CERN · Entity 126375 | OtherNon-Qualified Stock Option (right to buy) · Derivative | 20,000 | $38.43 Strike: $38.43 | $768,600.00 |
DisclosureSEC source: 0001209191-17-051657 · doc4.xml · derivative · entry 6 BURKE ZANE M · CIK 0001213555 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2022-03-09 Read SEC document |
| September 05, 2017 Filed Sep 6, 2017 16:45 UTC | CERNER Corp CERN · Entity 126375 | SaleCommon Stock | 94,000 | $67.47 | $6,342,180.00 |
DisclosureSEC source: 0001209191-17-051657 · doc4.xml · nonDerivative · entry 4 BURKE ZANE M · CIK 0001213555 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,799 F2 · price: Price reflects a weighted-average price for the transaction. Sale of shares took place at actual prices ranging from $66.91 to $67.96. F3 · price: Full information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, Cerner Corporation, or a Cerner shareholder. F1 · balance_after: Includes 18,000 shares of restricted common stock. Read SEC document |
| September 05, 2017 Filed Sep 6, 2017 16:45 UTC | CERNER Corp CERN · Entity 126375 | OtherCommon Stock | 64,000 | $44.62 | $2,855,360.00 |
DisclosureSEC source: 0001209191-17-051657 · doc4.xml · nonDerivative · entry 3 BURKE ZANE M · CIK 0001213555 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,799 F1 · balance_after: Includes 18,000 shares of restricted common stock. Read SEC document |
| September 05, 2017 Filed Sep 6, 2017 16:45 UTC | CERNER Corp CERN · Entity 126375 | OtherCommon Stock | 10,000 | $36.96 | $369,600.00 |
DisclosureSEC source: 0001209191-17-051657 · doc4.xml · nonDerivative · entry 2 BURKE ZANE M · CIK 0001213555 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,799 F1 · balance_after: Includes 18,000 shares of restricted common stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.